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Abstract
Current knowledge indicates that the aging process starts with subclinical changes at 
the molecular level. These include the accumulation of mutations, telomere attrition, and 
epigenetic alterations leading to genomic instability. Such defects multiply exponen-
tially over time, resembling a “snowball effect,” and eventually leading to morphological 
and functional deterioration of the brain, including progressive neuronal loss, reduced 
levels of neurotransmitters, excessive inflammation, and disrupted integrity of vessels, 
followed by infarction and microbleeds. Additionally, the decreasing efficiency of DNA 
repair mechanisms increases the susceptibility to reactive oxygen species and sponta-
neous mutagenesis, resulting in age-related neoplasia. Moreover, the malnutrition and 
malabsorption seen commonly in the elderly may cause deficiency of vitamin B
12
 and 
folic acid, both necessary for homocysteine metabolism, and lead to vascular damage. 
Altogether, these lead to brain damage in old age and greatly increase the risk of develop-
ing diseases of the central nervous system, such as stroke, epilepsy, Parkinson’s disease, 
Alzheimer’s disease, and other dementias.
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1. Introduction
Physiological aging starts after 60 years of age. Senescence in both animal models and 
humans is accompanied by alterations in the function of central cholinergic neurons. These 
changes essentially involve decreased levels of cholinergic receptors, reduced synthesis and 
release of acetylcholine, and a marked decrease in the number of muscarinic cholinergic 
neurons, all which may be linked to the age-related memory deficits, a typical change in 
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Alzheimer’s disease (AD) patients. Moreover, a decrease in the levels of dopaminergic neu-
rons of up to 40–50% may be observed in the substantia nigra and of dopamine in the stria-
tum at the end of the sixth decade of life, which are typical changes seen in patients with 
Parkinson’s disease (PD).
Increased longevity in much of the developed world appears to have lead to higher stroke 
incidence. Apart from an aging population, there is a significant impact of the growing preva-
lence of hypertension, diabetes, obesity, and disorders of the cardiovascular system on the 
increase in the incidence of stroke. The prevalence of these diseases increases with age.
Figure 1. Molecular factors associated with aging and age-related neurological diseases. The pathological changes 
starting at the molecular level induce oxidative stress and disturb cell cycle that affects cells of the aging organism 
and lead to systemic deterioration. The genetic variation may give rise to age-related neurological diseases. ROS—
reactive oxygen species, HHcy—hyperhomocysteinemia, AEDs—antiepileptic drugs, AD—Alzheimer’s disease, and 
PD—Parkinson’s disease.
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The most common causes of epilepsy in the elderly are vascular changes in the brain (approxi-
mately 5%) and degenerative diseases of the central nervous system (CNS) (10–20%). Seizures 
also occur in patients with AD, demyelinating diseases (multiple sclerosis, or MS), metabolic 
disorders, as well as in toxic and hormonal disorders, or in individuals with a history of brain 
injuries or CNS infection.
The mechanisms leading to the development of neurological disorders in the elderly have not 
been fully elucidated. There are no known mechanisms that regulate cell death in the aging 
brain. It is not known whether the age of various cells induces the process of apoptosis and 
other mechanisms of neuronal death, and what factors determine the susceptibility to devel-
oping neurological diseases in old age. Understanding the causes of the increased incidence 
of neurological diseases in the elderly may help in their prevention and improve quality of 
life in old age (Figure 1).
The following review is based on literature search through public databases, such as PubMed 
and Scopus, with the use of keywords: “aging,” “molecular mechanism,” “neurological dis-
eases,” “stroke,” “epilepsy,” “vascular dementia,” “Alzheimer’s disease,” “Parkinson’s disease,” 
and “brain tumor.” Subsequently, the authors selected eligible publications and performed fur-
ther searches through their references in order to find additional articles. The last search was 
performed in February 2017.
2. The molecular mechanisms of aging
The molecular mechanisms of aging include genome instability as a consequence of the 
accumulation of gene mutations, telomere attrition, and epigenetic alterations. Interestingly, 
instability occurs more frequently in some genome regions than in others. The association 
and interactions between the above mechanisms lead to the functional decline of aging 
organisms.
2.1. Aging due to DNA damage
The theory of aging establishes that somatic mutations happen randomly during an organism’s 
lifetime and their accumulation eventually affects key functions such as DNA synthesis, degra-
dation, and repair, consequently causing the “error catastrophe.” Genetic damage occurs both 
in nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) [1, 2]. However, mitochondria have 
an oxidative environment, due to multiple redox reactions in the electron transport chain, and 
a less efficient DNA repair system, which results in the accumulation of more damaged mDNA 
than nDNA [3, 4]. The decreased activity of autophagy and mitophagy may also be responsible 
for the accumulation of mtDNA mutations and mitochondrial dysfunction during aging [5].
The integrity and stability of DNA may be disrupted both by exogenous factors, such as 
physical, chemical or biological agents, as well as endogenous factors, including DNA rep-
lication errors and reactive oxygen species (ROS) [6]. Most of the damage to DNA occurs 
during the replication process, and the majority of this damage is corrected by a complex net-
work of DNA repair mechanisms. The mismatch repair (MMR) system provides the fidelity 
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of replication. The checkpoint response is activated by damage that is unrepaired and leads 
to cell senescence or death, which may also alter tissue and the homeostasis of the body. The 
loss of key MMR proteins has been observed during aging. The question becomes: is such 
deterioration a cause or an effect of senescence [7, 8]?
The cell cycle and repair processes are controlled by tumor protein 53 (p53, encoded by TP53 
gene), which is a pivotal regulator of multiple cellular processes, such as reversible and irre-
versible cell cycle arrest and senescence. The protein is activated by various stress factors to 
induce apoptosis or autophagic cell death, depending on the cell category [9]. The initiation 
of cellular aging is designed to prevent proliferation of damaged cells and tumorigenesis. 
Two main groups of signals activate p53: DNA damage and oncogenic stress. It has been 
demonstrated that loss of p53 function occurs in senescent cells, as 50% of human neoplasms 
possesses a mutated copy of the TP53 gene [10]. Moreover, the mutations in TP53 were 
observed also in age-related dementias, such as AD in both humans and its murine model 
[11, 12] (Figure 1).
2.2. The role of telomeres
Telomere attrition is another molecular mechanism responsible for senescence. Telomeres 
are a structural component of chromosomes localized at the end of each chromatid. They 
consist of DNA and telomere binding proteins. Telomere DNA is made up of the sequence 
5′-TTAGGG-3′ repeated 150–2000 times [13]. The main functions of telomeres are protection 
against loss of genetic information during replication and prevention of abnormal recombi-
nation, chromosome fusion, or chromosomal degradation by exonucleases [14]. During each 
cell division, the telomere sequence is shortened by a length of 50–200 base pairs (bp) and 
the structure of telomeres changes. This biological clock is considered to be one of the main 
mechanisms determining the number of possible cell divisions. Hayflick’s observations [15] 
on somatic cells specified the maximum number of divisions after which cells stop dividing 
but remain metabolically active. This maximum number is called the Hayflick limit and varies 
by tissue type and organism. It is known that a reduction in the number of divisions prevents 
the accumulation of mutations [16].
2.3. Epigenetics of aging
Epigenetic alterations are another molecular mechanism involved in aging and include DNA 
methylation and histone modifications [17]. The epigenome becomes deregulated with age. 
Global levels of DNA methylation decrease with age, and changes in the methylation profile may 
lead to age-associated immune deficiency [18]. The chemical modification of histones  include s 
acetylation, methylation, phosphorylation, ubiquitination, deamination, citrullination, sumoy-
lation, ADP (adenosine diphosphate) ribosylation, and proline isomerization and lead to 
changes in histone-DNA or histone-histone interactions [19]. Both changes in the DNA meth-
ylation pattern and histone modifications can directly alter chromatin packaging, resulting in 
different parts of the DNA being exposed to transcriptional factors and results in the expres-
sion of different genes. Epigenetic studies have demonstrated progressive changes at the 
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transcriptomic level associated with aging. The age range of 49–56 years in humans seems to 
be critical in transcriptional senescence. Changes in gene expression, either their increase or 
decrease, are a longitudinal and dynamic process [20] (Figure 1).
2.4. Aging of the brain
Furthermore, senescence comprises aging of the cerebral white matter (WM) and gray matter 
(GM), including progressive neuronal loss, decreased levels of neurotransmitters, increased 
inflammation, disrupted integrity, lesions, infarction, and microbleeds [21]. Aging affects not 
only neurons but also glial cells (astrocytes, oligodendrocytes, microglia), vascular cells, and 
the basal lamina matrix and interferes with their functions such as maintaining metabolic 
and ion homeostasis in the CNS, regulating the cerebral blood flow, impulse conduction, and 
phagocytosis [22]. During aging, the reduction of WM volume is almost threefold higher (loss 
of 28% of neurons) than the reduction of GM volume (10% of neurons). Thus, changes in WM 
may result in behavioral and cognitive decline in the elderly. Additionally, the ability for WM 
repair has been found to be decreased in older individuals. Changes in WM are observed in 
diseases, such as stroke, PD, and AD [21].
Multiple molecular changes take place during aging, and these form a vast network of inter-
actions. This makes it nearly impossible to determine if age-related diseases are caused by a 
snowball effect of senescence, or if the converse is true: that these diseases are the result of 
individual variability. It seems that both hypotheses may be true, as aging is an important 
risk factor for diseases such as stroke, epilepsy, PD, AD, and brain tumors, but not a certain 
causative factor (Figure 1).
3. Neurological diseases associated with aging
3.1. Stroke
According to World Health Organization (WHO), stroke is defined as “rapidly developing 
clinical signs of focal (or global) disturbance of cerebral function, lasting more than 24 hours 
or leading to death, with no apparent cause other than that of vascular origin” [23]. There 
are two main types of stroke, ischemic and hemorrhagic, which have different pathogenesis.
3.1.1. Ischemic and hemorrhagic stroke
In an ischemic stroke, the blood supply to some brain areas is reduced due to narrowing or 
complete occlusion of arteries, which leads to dysfunction of this part of the brain tissue. The 
molecular mechanisms involved in the pathomechanism of ischemic stroke include progres-
sive damage of the blood-brain barrier (BBB) due to loss of integrity, degeneration or death 
of neurons, glial reaction, and infiltration of immune cells. Ischemic stroke represents 85–90% 
cases of stroke [24, 25]. Age-related changes in WM are thought to increase the risk for stroke, 
poststroke death [26], and ischemic injury after stroke [27]. One of the molecular features 
Aging and Neurological Diseases
http://dx.doi.org/10.5772/intechopen.69499
67
of ischemic stroke in the elderly is excitotoxicity due to changes in protein expression (e.g. 
increase in GLT-1, a transporter for glutamate) and production of ROS. The generation of 
ROS leads to the death of oligodendrocytes and to the disruption of axons within WM. In the 
aged brain, the functional decline of mitochondria and antioxidant systems is associated with 
greater oxidative stress and worsen the WM injury upon ischemia [21].
Hemorrhagic stroke may be caused by cerebral hemorrhage and subarachnoid hemorrhage 
as a result of damage to the brain’s blood vessels by chronic hypertension, cerebral arterio-
venous malformation, intracranial aneurysm, disambiguation, cerebral amyloid angiopa-
thy, or drug-induced bleeding. The molecular basis of such a hemorrhage is represented by 
cytotoxicity of blood, hypermetabolism, excitotoxicity, oxidative stress, and inflammation 
[28, 29].
3.1.2. Senescence, civilization diseases, and stroke
The American Heart Association has reported that stroke is the fifth cause of death in the 
United States [30]. The risk factors of stroke are divided into modifiable (e.g. hypertension 
and other cardiovascular diseases, migraine, diabetes, dyslipidemia, diet, addictions) and 
unmodifiable (age, sex, race, genetic factors). Among the unmodifiable risk factors, the most 
important is age [31]. The risk of stroke increases exponentially with age in both men and 
women. It is estimated that the incidence of stroke doubles with each decade of life after the 
age of 55 and affects as many as 5% of people over the age of 65 [32]. It is known that the 
majority of modifiable risk factors, such as hypertension, atrial fibrillation, hyperhomocys-
teinemia (HHcy), and inflammatory processes (e.g. periodontal disease, infections, increased 
hs-CRP), are more common in the elderly. The effect of aging on the cardiovascular system 
is cumulative [33]. Atrial fibrillation occurs in 5% of individuals aged 70 or above and is a 
cause of one quarter of stroke incidents in patients at the age of 80. The risk of stroke can be 
decreased by antithrombotic therapies [34].
The serum total homocysteine (Hcy) concentration is another independent risk factor of isch-
emic stroke in the elderly, as it correlates with thrombosis. The population attributable risk 
of stroke incidence in high Hcy levels (>17.4 μmol/L) changes with age and was estimated 
at 21 and 26% for age 40–59 years (men and women, respectively) and at 35 and 37% for 
individuals over 60 years of age (men and women, respectively) [35]. HHcy (level of Hcy 
more than 15.0 μmol/L) promotes the development of atherosclerosis. Clinical studies have 
shown that HHcy has a toxic impact on both the vascular and nervous systems and may be 
observed not only in stroke but also in PD, mild cognitive impairment (MCI), and epilepsy 
[36]. Supplementation of folate and vitamin B
12
 is essential in the treatment of HHcy, but 
folate alone does not reduce the risk of stroke [37].
Two thirds of the population aged over 65 years suffers from hypertension [31]. Hypertension 
has been proven to increase fourfold the risk of stroke; as the blood pressure increases, so 
does the probability of suffering stroke. Fortunately, a blood pressure reduction of about 
10/5 mmHg decreases the risk of stroke by about 35% [33]. Hypertension is often linked with 
obesity, abnormalities in lipid profile, and type 2 diabetes. Together, these comorbidities 
contribute to atherosclerosis and thromboembolic stroke.
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Diabetes has been found to have a greater impact in developing stroke in women than in 
men. Diabetes is a significant independent contributor of stroke in older women [38, 39]. 
However, the risk of stroke in diabetic patients can be decreased with proper intervention 
and treatment. The Systolic Hypertension in the Elderly Program has shown that antihy-
pertensive treatment in individuals with diabetes can reduce the risk of stroke by about 
20% [40].
Disturbances in the lipid profile should be regularly reviewed and treated as necessary, as 
they are another contributor to stroke. Independent studies have shown that high levels of 
total cholesterol (in the 240–270 mg/dL range) [41–43] and triglycerides [44, 45] as well as a low 
level of high-density lipoproteins (HDL, up to 35 mg/dL) [43, 46, 47] increase the incidence of 
ischemic stroke. According to the Heart Protection Study, statin therapy in the elderly group 
can reduce the risk of a first stroke by 29% [48]. Another side of the coin is obesity, defined 
as body mass index (BMI) >30 kg/m2, or abdominal obesity, defined by a waist circumference 
>102 cm (men) and >88 cm (women) [33]. It is known that abdominal obesity is a stronger 
predictor of stroke than BMI [49].
Moreover, it has been observed that infection with some pathogens may cause acute stroke 
within a week; these pathogens are Chlamydophila pneumoniae, Haemophilus influenzae, 
Mycoplasma pneumoniae, Helicobacter pylori, Cytomegalovirus, Epstein-Barr virus, and Herpes 
simplex virus types I and II. This occurs due to the activation of leukocytes and increased ten-
dency for thrombosis at the site of atherosclerotic plaque. Because of immune deficiencies, the 
elderly are more susceptible to infections and, therefore, to postinfection complications [33].
It should be mentioned that controlling and regulating the modifiable risk factors is 
extremely important in stroke prevention. Older people tend to pay more attention to 
stroke avoidance. Epidemiological studies performed in the USA assumed that, in the 
last decade, the stroke death rate declined more in subjects after the age of 65 than in the 
younger population [30].
Stroke is a heterogeneous syndrome, with possible genetic background. Single-gene dis-
eases may cause rare, hereditary disorders for which stroke may be a primary manifestation. 
Recent studies suggest that common and rare genetic polymorphisms that induce diabetes, 
hyperlipidemia, or hypertension may activate specific stroke mechanisms causing danger-
ous angiopathies [50]. For instance, the genetic variation at chromosome 16 (locus q24.2) had 
been shown to induce small vessel stroke. Traylor et al. using modern GWAS method have 
found that rare variant rs12445022 in ZCCHC14 gene may induce small vessels dysfunc-
tion, thus greatly increase the risk of stroke [51]. Another interesting genetic factor studied 
in stroke is a polymorphism in BDNF gene (rs6265), which results in amino acid change 
(Val→Met) in the precursor protein, causing a reduction in brain-derived neurotrophic fac-
tor (BDNF) activity, which plays a role in rehabilitation after stroke. The studies show that 
concentrations of BDNF were decreased in acute ischemic-stroke patients compared to con-
trols. BDNF signaling is dependent on the genetic variation which could affect an individu-
al’s response to recovery after stroke. The rs6265 polymorphism may also affect the risk of 
ischemic stroke, post-stroke outcomes and the efficacy of the various forms of rehabilitation 
[52] (Figure 1).
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3.2. Epilepsy
Epilepsy is one of the most common neurological diseases, with approximately 50 million suffer-
ers worldwide. Epilepsy is a collection of somatic, vegetative, and/or mental symptoms, which 
may be the result of morphological or metabolic changes in the brain. Although the disease has 
a chronic character and had long been thought to be connected with events in infancy or child-
hood, epidemiological studies have revealed that there is pronounced incidence of epilepsy in 
people over 65 years of age [53, 54]. To date, many various causative factors have been associated 
with epilepsy. However, the etiology of the disease remains unknown in 65–75% of patients [55].
Epilepsy that develops after the age of 60 is symptomatic in the vast majority, although gener-
alized epilepsy may also rarely manifest in the elderly [56]. Epileptic seizures are often under-
diagnosed in that age group. The symptoms are usually recognized as memory disorders or 
mental changes of uncertain origin [57]. Risk factors for epilepsy and seizure etiology vary 
with age. The most common mechanism of pathogenesis of new-onset epilepsy and seizures 
in the elderly may be associated with cerebrovascular diseases (CVDs), neuron degenerative 
disorders, intracerebral tumors, and traumatic head injury [58, 59].
3.2.1. Epilepsy and cerebrovascular diseases
CVDs account for 30–50% of all identified causes of epilepsy in the elderly [60, 61]. Epilepsy 
attacks may be affected by a stroke and may occur immediately after an ischemic event or 
be delayed. Seizures may also be the first clinical manifestation of brain ischemia or hemor-
rhage, increasing the risk to develop epilepsy within the first year after the vascular episode 
by 20 times. The study of Alberti et al. [62] showed that hemorrhagic transformation of an 
ischemic stroke is a predictive factor for epilepsy and may also be related to the disruption 
of the BBB [63]. Numerous genetic factors may be engaged in epileptogenesis. According to 
Yang et al. [64], mitochondrial aldehyde dehydrogenase 2 (ALDH2, encoded by the ALDH2 
gene) has a protective effect in CVDs. Nevertheless, allele A of the rs671 polymorphism in the 
ALDH2 gene was shown to be connected with post-stroke epilepsy due to decreased activ-
ity of ALDH2 leading to accumulation of the potential ALDH2 substrate—4-hydroxynonenal 
(4-HNE), considered to be a specific marker of oxidative stress and involved in myocardial 
and cerebral ischemia. Zhang et al. [65] suggest that the T allele of the -1C/T polymorphism 
in the CD40 gene may be associated with susceptibility to poststroke epilepsy (Figure 1). The 
proposed mechanism includes raised plasma concentrations of sCD40L, which is involved 
in the inflammatory response. Moreover, poststroke epileptogenesis was shown to be associ-
ated with lifestyle factors (alcohol use), acute metabolic disturbances (hyperglycemia), non-
CNS comorbidities (type 1 or 2 diabetes, hypertension, coronary heart disease or myocardial 
infarction, as well as peripheral infections), CNS diseases (early seizures, depression or use of 
antidepressants, dementia), and pharmacotherapy (statins) [66].
3.2.2. Epilepsy due to head trauma
Another causative factor of epilepsy in the elderly may be head trauma. Due to an increased 
likelihood of imbalance, older people are more prone to falls causing head injuries. Acute events, 
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such as skull fractures, subdural hematoma, brain contusion, accidental injury, concussion, or 
loss of consciousness, were shown to be associated with increased risk of posttraumatic epilepsy 
[67]. Moreover, various genetic factors were shown to be associated with head injury as a risk fac-
tor for late posttraumatic seizures. Diaz-Arrastia et al. [68] showed that carriers of the pathogenic 
APOE E4 allele were more likely to develop epilepsy after suffering acute head trauma (Figure 1).
3.2.3. Epilepsy due to brain tumor
Epileptic seizures are common symptoms of brain tumors (BTs) in 20–40% of patients. The study 
of de Assis et al. [69] demonstrates that BTs related to epilepsy include primary CNS lymphoma, 
meningioma, anaplastic ependymoma, and anaplastic astrocytoma. The highest incidence of 
epilepsy occurs in low-grade tumors like primary astrocytoma, oligodendroglioma, mixed 
astrocytoma WHO grade I and II, as well as meningiomas. It seems that the incidence of seizures 
is inversely correlated to the grade of the malignancy. Age is a risk factor for increased mortal-
ity in those BT patients who develop seizures. Epilepsy attacks also appear in 67% of patients 
with melanocytic brain metastases, in 48% patients with lung cancer metastases, in 33% patients 
with breast cancer, and in 55% of patients in whom the primary cancer type was unknown. 
Unfortunately, BT-related epilepsy is characterized by pharmacological resistance [69, 70].
3.2.4. Biochemical factors in epilepsy
Hcy seems to have additional and interesting significance for the development of epilepsy. As 
stated earlier, HHcy has demonstrated an association with several disorders, including epi-
lepsy [71]. High Hcy concentration has been shown to be related to numerous factors, includ-
ing lifestyle (smoking, high consumption of alcohol, caffeine), age (due to the weakening of 
the excretory function of the kidneys, malabsorption of vitamin B
12
 in the stomach, hormonal 
disorders, e.g. in women during and after menopause), comorbid diseases, pharmacotherapy 
(e.g. antidiabetic drugs or fibrates), or unbalanced diet (deficiency of vitamin B
12
 or folic acid) 
[72–75]. Moreover, Schwaninger et al. [76] demonstrated that prolonged treatment with anti-
epileptic drugs (AEDs) may increase the plasma concentration of Hcy. On the other hand, the 
authors were not able to conclude whether the HHcy in epilepsy patients was a sole effect of 
pharmacotherapy or a causative factor of the disease.
Seizures may also occur in metabolic disorders, because of multiple comorbidities and poly-
pharmacy. There should be a high index of suspicion for electrolyte imbalance, especially 
hyponatremia and hypoglycemia, in this group of patients. Other metabolic disorders, such 
as hyperglycemia and uremic or hepatic encephalopathy, are less specific to this age group 
[77]. The role of alcohol appears to be less important in the elderly than in young adults, but 
should not be neglected [78], as it may intensify the number of calcium channels and promote 
seizure activity by increasing the concentration of neurotransmitters [79].
3.2.5. Epilepsy in degenerative diseases
AD is a significant risk factor of epilepsy in the elderly. Imfeld et al. [80] suggested that 
patients with a longer history of AD (≥3 years) may have a higher risk of developing seizures 
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or epilepsy than those with a shorter duration of disease. Similar results were presented by 
Amatniek et al. [81], who observed that the incidence of seizures increased as the disease 
progressed; the cumulative incidence over 7 years was 8%. The risk of seizure onset is higher 
in AD patients with hyperlipidemia and severe dementia [82]. The epileptogenetic mecha-
nism has not yet been elucidated in patients with neurodegeneration. It might be associated 
with β-amyloid (Aβ) deposition, neuronal loss and gliosis, and antidementia drugs [83, 84]. 
High levels of Aβ are considered a cause of AD, but they are also related to synaptic activ-
ity. Aβ serves as a potent regulator of synaptic transmission, causing presynaptic facilita-
tion at relatively low Aβ concentrations and postsynaptic depression with higher Aβ levels. 
The modulation of synaptic transmission has an important effect on producing epileptiform 
activity [85].
Another degenerative disorder which may potentially induce seizures is MS, a chronic disease 
of the CNS. MS usually occurs in young adults (aged 20 to 40 years). However, 1.1–12% of MS 
patients experience the first symptoms of the disease after the age of 50 [86]. The prevalence 
of seizures among MS patients was shown to be higher than the general population, which 
may indicate the relationship between seizures and MS [87]. One possible explanation is that 
MS lesions act as epileptogenic sites [88]. Generally, a small fraction (2.5%) of MS patients 
develop seizures [89]. The study of epilepsy in the elderly among MS patients is inconclusive, 
but clinicians should be aware of the risk of epilepsy in people with MS [88].
3.3. Aging and dementia
Dementia—as a form of cognitive decline—is strongly associated with old age. Almost 10% of 
those older than 65 years suffer from some kind of memory impairment. The most common 
causes of dementia include AD and vascular dementia (VaD). The prevalence of dementia 
increases with age, affecting nearly 50% of the population over 85 years of age. Dementia is a 
progressive disorder, finally leading to severe disability and complete dependence of suffer-
ers on caregivers [90].
3.3.1. Vascular dementia
VaD was initially understood to be an advanced effect of repetitive brain lesions [91]. The 
development of brain imaging techniques revealed that silent ischemic lesions appeared 
to be quite common and later became known as a significant cause of dementia [92, 93]. 
Epidemiological studies have shown that vascular dysfunction causes 10–20% dementia cases 
[94, 95]. The frequency of VaD in the general population varies from 1.2 to 4.2% of individuals 
over 65 years, depending on the methodological approach [94, 96]. The prevalence of VaD is 
strongly connected with age. A Canadian study described that frequency of vascular cognitive 
impairment increased from 2.0% in those aged 65 to 74 years to 13.7% in those over 85 years 
of age [97]. A meta-analysis from 1998, synthesizing the results of 23 studies from around 
the world, confirmed the trend of increasing incidence of VaD in senescence [98]. Increasing 
longevity in many populations has also increased the importance and burden of vascular-
related memory deficits. A long-term survey demonstrated that the incidence of post-stroke 
dementia between 1984 and 2001 had doubled [99].
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Several studies have analyzed the risk factors, other than age, of CNS vascular lesions. They 
identified hypertension, heart disease, diabetes with insulin resistance, and dyslipidemia to 
be related to an increased risk to develop VaD. It is important to note that the results obtained 
by different authors occasionally contradict each other [100–109]. The cluster of cardiovascu-
lar risk factors, also called “metabolic syndrome,” that include dyslipidemia, obesity, hyper-
tension, and insulin resistance, has also been shown to be associated with VaD [110, 111]. 
Additionally, patients with fully symptomatic metabolic syndrome obtained lesser scores 
in neuropsychological testing [112]. Moreover, HHcy, previously associated with vascular 
diseases and stroke, was shown to be associated with VaD [113].
Many studies have also demonstrated that a symptomatic stroke incident, occurring mostly 
in the elderly, may inflict memory deficits in 6 to 32% of patients, depending on the follow-
up period (3 months—20 years) [114–128]. MCI preceding stroke increases the probability of 
post-stroke dementia [129, 130], and memory decline seemed to progress more rapidly with 
later stroke episodes [131]. Similarly, recurrent stroke was associated with greater cognitive 
impairment when compared with patients with a single vascular incident [122] (Figure 1).
3.3.2. Alzheimer’s disease
AD is the most common form of dementia in older adults [132]. AD is a progressive incur-
able neurodegenerative disease where aging is the primary risk factor. AD may be divided 
into two main clinical subtypes: familial AD (FAD) characterized by early onset (before 65 
years of age) and, frequently, the presence of mutations in the APP, PSEN1, and PSEN2 
genes. This genetic triad is responsible for nearly half of the FAD cases seen [133]. However, 
mutations in these genes occur very rarely in the human population. Subsequently, the 
majority (90%) of AD cases are sporadic (SAD) and manifest mostly in patients over 65 years 
of age. The multifactorial character of the disease makes it extremely difficult to determine 
a causative factor for SAD [134]. To date, nearly 700 genes have been associated with AD, 
although the most investigated risk factor for SAD remains the E4 allele of the APOE gene 
[90, 135, 136].
The diagnosis of probable AD is based on clinical criteria [137], however, the disease may be 
diagnosed with certainty only after death, by histopathologic study of the brain, revealing 
characteristic lesions: Aβ plaques and neurofibrillary tangles (NFTs) formed by hyperphos-
phorylated protein tau. Aβ is formed via pathologic cleavage of (amyloid precursor protein 
(APP), encoded by the APP gene) by β- and γ-secretases (encoded by the BACE and PSEN 
genes, respectively). The appearance of Aβ plaques and NFTs seems to be one of the causes 
for neurodegeneration: the morphological and functional loss of neurons and synapses, as 
well as excessive neuroinflammatory processes occurring in AD brains. Martin et al. [138] 
showed that aging and Aβ pathology may activate similar receptors on microglia and mono-
cyte-derived macrophages. Moreover, carriers of the APOE E4 allele and rare variants in other 
genes, such as HLA-DRB5/DRB1, INPP5D, MEF2C, CR1, CLU, and TREM2, may exhibit an 
even stronger activation of microglia than noncarriers [139]. This explains why older patients 
with unfavorable genetic variants are more prone to excessive neuroinflammatory responses 
leading to neuronal loss and dementia.
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The neurons mostly affected by AD are cells expressing acetylcholine (ACh) receptors, also 
called “cholinergic neurons” (AChN). Loss and degeneration of this type of cells is another 
hallmark of dementia and occurs gradually with age and the course of the disease [140]. The 
age-related degeneration of AChN leads to decreasing levels of ACh in the brain. ACh has 
been proven to be the neurotransmitter that is most reduced in the majority of AD patients 
[141]. It seems that genetic factors, such as the presence of the pathogenic APOE E4 allele, may 
also significantly influence the production and release of ACh. The study on transgenic mice 
expressing human APOE indicated that age-related decrease in ACh levels released by the 
hippocampus was more prominent in mice with human APOE E4/E4 than in mice with APOE 
E3/E3 variants [142] (Figure 1).
The main cholinergic structure of the brain is the basal forebrain (BF), the underlying neu-
rodegeneration of which may be observed in advanced aging as well as in the early phase 
of AD and other dementias [143]. BF degeneration occurs due to a decrease in cholinergic 
neurotransmission and a reduction in the amount of ACh in synaptic clefts, followed by a 
loss of cholinergic receptors, finally resulting in AChN death. This process, according to the 
“cholinergic deficit hypothesis,” results in behavioral and cognitive impairment, especially 
learning difficulties, which advance rapidly with age [144].
It is worth noting that in AD, similarly to VaD and stroke, the concentration of Hcy may be 
increased and so may inflict damage to the vasculature, thereby leading to decreased blood 
flow and inefficient nutrient delivery to neurons. Subsequently, the starving cells become 
more prone to ROS and apoptosis. HHcy is also associated with a decrease of the glutathione 
pool, the deficiency of which results in the deterioration of protection mechanisms from free 
radicals, further contributing to neuronal loss and neurodegeneration [145].
3.4. Parkinson’s disease and aging
PD is an age-related neurodegenerative disease characterized by resting tremor, rigidity, and 
bradykinesia. The number of PD patients increases over the years due to population aging. 
The exact pathomechanism of PD remains unclear, but it is known that the degeneration 
process starts many years before the occurrence of clinical symptoms. The hallmark of PD 
is dopaminergic (DA) neuron death in the substantia nigra (SN), which is a result of Lewy 
body (LB) formation due to impairment of the ubiquitin-proteasome system and disturbances 
in the proteins alpha-synuclein (ASN) and Parkin [146, 147]. Molecular characteristic of PD 
include increased ROS production due to mitochondrial dysfunction and accompanied by 
decreased mitophagy [148], neuroinflammation and loss of neurotrophic factors [149, 150], 
exposure to (1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)) or paraquat [151], 
exposure to trichloroethylene or polychlorinated biphenyls [152], iron (the level of which 
increase in the SN with age), copper, manganese [153, 154], or mutations in PARK genes [155]. 
Mitochondrial dysfunction is associated with aggregation of ASN, apoptosis, accumulation 
of damaged mitochondria, and changes in the activity of complex 1 [156]. A decline in mito-
chondrial function as well as inflammation and changes in DA metabolism are linked with 
the aging process.
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Advancing age is the most important risk factor of developing PD. PD affects about 1% of the 
population over the age of 60 and 5% over the age of 85 [157]. It has been since 1987 that the 
loss of DA neurons progresses with aging, but the rate of the physiological process is slower 
than that seen in PD [158]. Moreover, LB may be present in elderly individuals without PD 
[159]. The aging brain is also more prone to stressor stimuli and generation of ROS, which 
results in the injury and eventual death of SN neurons. On the other hand, a decreased level or 
even loss of ROS scavengers, e.g. neuromelanin, in the PD brain may be a cause of DA neuron 
damage rather than an effect of this damage [157].
Many epigenetic mechanisms, such as changes in DNA methylation profile and histone modi-
fication, play an important role in aging and contribute to PD. The epigenetic clock can be 
characterized just by measuring the DNA methylation pattern. Interestingly, PD patients rep-
resent an increased acceleration in aging when compared to controls of the same age [160]. 
Hypomethylation of SNCA, the gene encoding ASN, leads to an increased expression of ASN 
and has been observed in the SN of PD patients [161]. ASN can also influence histone acetyla-
tion (a feature of transcriptionally active genes) and enhance ASN fibrillation [162].
During normal aging, the functional decline of the BBB can cause neuroinflammation and 
the development of neurodegenerative diseases [163]. Disturbances in BBB permeability 
observed in the senescence process may be involved in the genesis of WM lesions, which may 
also affect the efficacy of treatment. In the course of aggregation of ASN in PD, elevated ROS 
production and increased levels of proinflammatory cytokines or toxic agents may intensify 
disruptions of the BBB [164].
HHcy observed in PD may be involved in the disease pathogenesis; however, the exact mech-
anism of interaction remains unrecognized. Both HHcy and age are risk factors for develop-
ing dementia in PD patients [165]. Treatment with L-dopa may be responsible for HHcy in 
individuals with PD [166]. In those patients, Hcy is formed in the methylation of L-dopa via 
catechol-O-methyltransferase (COMT) [167]. Other side effects of L-dopa at the molecular 
level include increased oxidative stress, as well as altered concentrations of catecholamines 
and apoptotic proteins [147]. Damage of DA neurons due to oxidative stress may be enhanced 
by elevated Hcy (Figure 1). A study performed on mice has shown that elevated Hcy increases 
the sensitivity to MPTP and developing PD-like dysfunction [168].
3.5. Brain tumors in the elderly
Another type of CNS disease, manifesting particularly in the elderly, are brain tumors, classi-
fied according to WHO criteria to four grades, with grade IV considered most malignant [169]. 
In adults, the most prevalent type of primary brain tumor is malignant glioma (MGs), with 
the highest incidence between 40 and 65 years of age. The majority of MGs are sporadic, with 
ionizing radiation as the only known risk factor. The most common type of glioma is glio-
blastoma multiforme (GBM), qualified as a WHO grade IV astrocytic tumor, and constituting 
about half of all MGs with the highest incidence in the elderly, between 70 and 90 years of age 
[170–172]. Old age is a negative prognostic factor in GBM [173]. One of the most significant 
characteristics of GBM is an increasing prevalence with age; thus, due to an increasing median 
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length of life, the number of patients is expected to grow in the coming decades. Other types 
of brain tumors common in the elderly are primary CNS lymphomas (PCNSLs) and menin-
giomas [174].
GBM comprise a rather heterogenic group of neoplasms, with two major types: primary glio-
blastomas (85–90%) and secondary GBMs that arise from low-grade astrocytomas (10–15%) 
[175]. Although both types are indistinguishable under the microscope, they appear to differ 
genetically. Genetically, primary GBMs exhibit by amplification and mutation of the EGFR 
gene, a lack of heterozygosity on chromosome 10q, inactivation of the PTEN homolog gene, 
and only rare occurrence of mutations in the IDH and TP53 genes. Conversely, the genetics 
of secondary GBM are characterized by mutations in the IDH and/or TP53 genes, as well as 
platelet-derived growth factor receptor activation [176]. A gene expression-based GBM clas-
sification was established by The Cancer Genome Atlas (TCGA) Research Network in 2010. The 
authors distinguished four subtypes of GBM. Characteristics that differentiate the subtypes at 
most were indicated as follows: proneural GBM has alterations of the PDGFRA gene and point 
mutations of IDH1, classical GBM has EGFR aberrations, and mesenchymal demonstrates GBM 
aberrations in NF1. The fourth subtype, neural GBM, is characterized by the expression of neu-
ron markers such as NEFL, GABRA1, SYT1, and SLC12A5. Each subtype of GBM differs in its 
sensitivity to radiotherapy and chemotherapy, thus determining the genetic type of a surgically 
removed or biopsied lesion could protect patients against unnecessary ineffective therapy [177].
Unfortunately, GBMs are mostly incurable in the elderly, with most of these patients surviv-
ing less than 6 months [171]. Diagnosis of primary brain tumors in old age can be further 
complicated and delayed due to nonspecific symptoms that can be masked by physical and 
cognitive changes observed in the normal aging process [178]. Moreover, elderly patients are 
an underrepresented group in many clinical trials [179]. The literature data indicate that, at 
the close of the twentieth century, the chances of receiving a treatment, be that surgery and/
or radiotherapy, were decreasing as the patient got older. Treatment mostly took place for 
82% of patients younger than 65 years of age, whereas only 47% of people older than 65 years 
and merely 25% of patients older than 75 were subjected to any kind of therapy. Additionally, 
patients treated with radiotherapy and/or surgery had a significantly lower survival rate as 
they crossed the age border of 60 years [180].
Although pathological processes differ depending on the glioma subtype, there is a common 
core of molecular events. Growth factor receptor tyrosine kinases cause downstream signal-
ing by activation of extracellular signal-regulated kinases (ERK) or protein kinase B (Akt) 
pathways. Lack of p53 activation is followed by the loss of the ability to activate DNA repair 
processes and cell death by apoptosis. An additional adverse characteristic occurring in GBM 
is that the cells provoke the secretion of vascular endothelial growth factor (VEGF), which 
is responsible for angiogenesis. The secretion of VEGF by GBM results in vascularization of 
the tumor, elevation of capillary permeability of the BBB, and creation of extracellular edema 
[181]. Finally, due to vasculature growth, there is progression of tumor invasion [182].
Although these brain tumors are very invasive, it is important to note that, depending on the 
tumor subtype, they may be effectively treated in elderly patients by maximally safe surgical 
resection, radiotherapy, and/or chemotherapy with Temozolomide, a drug which is especially 
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preferable as first-line treatment in patients with the MGMT promoter [179, 183]. In addition 
to radiotherapy and/or Temozolomide, Bevacizumab (BV, Avastin®) is being studied for the 
treatment of brain tumors. BV is a humanized IgG1 monoclonal antibody targeting VEGF 
with high affinity and inactivating the growth factor. Thus, BV promotes tumor regression 
and helps to decrease the risk of cerebral edema [184]. Interestingly, it has been demon-
strated that, although old age is a negative prognostic factor, BV was more effective in older 
patients (≥55 years of age); those treated with BV remained in better health longer and used 
lower doses of steroids. These findings were in line with the study published by Nghiemphu 
et al. [185], who demonstrated that expression of VEGF was 1.4-fold higher in older patients 
than in younger subjects, and so inhibition of VEGF could give a more positive outcome in 
these patients.
The increased incidence of brain tumors in the elderly may also be due to decreased efficiency of 
repair mechanisms. Inactivation of genes involved in DNA repair, such as the above-mentioned 
TP53 and MGMT, may advance with age. This may lead to increased accumulation of DNA dam-
age, in turn resulting in further activation of proto-oncogenes and silencing of tumor suppressor 
genes. Such changes, inflicted either by mutation or epigenetic changes, may cause additional 
destabilization of cellular repair mechanisms, increasing the susceptibility to ROS and spontane-
ous mutagenesis, and triggering the positive feedback loop of neoplasia [186] (Figure 1).
4. Summary
The molecular mechanism of aging includes genome-wide changes such as genomic instabil-
ity due to accumulation of mutations, telomere attrition, and epigenetic alterations. These 
changes collect over the years during the life of the organism, leading gradually to morpho-
logical and functional deterioration. The brain seems to be particularly vulnerable, as neurons 
generally do not divide and their pool decreases with the passage of time. Structural changes 
in the senescent brain affect mostly the cerebral WM and GM; these effects include progres-
sive neuronal loss, decreased levels of neurotransmitters, increased inflammatory processes, 
and disrupted integrity of vessels and the BBB followed by infarction and microbleeds. These 
changes may lead to degenerative diseases, such as PD and dementias.
The frequently observed malnutrition and malabsorption syndrome in the elderly may 
cause decreased concentrations of the vitamins necessary for Hcy metabolism. This in turn 
results in increased injury to the cerebral vasculature, leading to degeneration and strokes. 
Consequently, progressive age-related vascular damage of the brain develops, additionally 
connected to an increased prevalence of epilepsy in the elderly.
An increased incidence of brain tumors may also be observed in old age, probably as an effect 
of the diminished efficiency of repair mechanisms. The inactivation of genes involved in DNA 
repair has been shown to advance with age. Such alterations, inflicted either by epigenetic 
changes or mutation, may cause further destabilization of immunologic systems and cellular 
repair mechanisms, thus increasing the susceptibility to ROS and spontaneous mutagenesis 
and resulting in uncontrolled cellular growth and age-related neoplasia (Figure 2).
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Figure 2. Changes during the senescence process may be associated with neurological diseases. The pathological 
changes starting at the molecular level affect cells of the aging organism and lead to systemic deterioration, giving rise 
to age-related neurological diseases. ROS—reactive oxygen species, WM—white matter of the brain, and GM—gray 
matter of the brain.
In summary, the senescence mechanisms start at a molecular level and gradually lead to mor-
phological disintegration and functional loss of brain cells. Finally, they lead to the deteriora-
tion of the CNS and an increased risk of developing neurological diseases.
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